BIOCON

Biocon Limited
Mid-capPharma

What the six lenses say about BIOCON — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹391.4
2026-09-08
VWAP · 1Y anchor
₹395
-0.8% from VWAP
P/E · TTM
143.9×
TTM EPS ₹2.7
52-week range
52%
position low→high
RSI(14)
30
momentum

Own sector index

Pharma
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How BIOCON’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
3.0
avg conviction decile
Leadership
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD438

The actual numbers

Price vs VWAP (1y)-0.8%
EMA trend stackMixed
Price vs 200-EMA-1.7%
Price vs 50-EMA-5.7%
RSI(14)30
RS vs Nifty 500 · 3M-8.8%
RS vs sector · 3M-14.8%
52-week range52%
Volume vs 30d avg0.91×
Volume vs 60d avg0.62×
ATR(14) · volatility10.0
Bollinger width · vol contraction0.087
FundamentalD132

The actual numbers

Return on equity (ROE)1.4%
Return on capital (ROCE)3.8%
Operating margin8.5%
Net margin2.2%
Revenue growth · YoY+10.9%
EPS growth · YoY-67.8%
Debt / equity0.45×

Full 8-quarter history in the financials table below.

ValuationD724

The actual numbers

P/E (TTM)143.9×
TTM EPS₹2.7
52-week range52%
CatalystD1086

The actual numbers

Earnings & momentum116
Capital actions52
Governance180

Every filing in the corporate-announcements panel below.

FlowD242

The actual numbers

Promoter holding44.9%
Delivery · 30d avg51.5%
Up/down-day asymmetry-2.8pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D4 + D2 ) ÷ 2 = 3.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Watch
38
Conviction score 38/100 · avg-decile strength 3.0/10

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-1.0pp
-3.7pp
-6.9pp
-7.2pp
+2.9pp
+11.5pp
Nifty 500
Broad-market baseline
-1.1pp
-3.7pp
-7.9pp
-8.8pp
-2.8pp
+6.3pp
Sector
Own-sector index
-10.8pp
-14.8pp
-16.0pp
-14.5pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

BIOCON daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
391.40-6.00

Relative strength

RS vs baseline · rebased to 100

BIOCON ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
105.20-1.16

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)3,4333,5903,8214,4173,9424,2964,1734,517
↳ change QoQ+4.6%+6.4%+15.6%-10.8%+9.0%-2.9%+8.2%
EBITDA (₹cr)1,7877448051,0787498358341,020
EBITDA margin52.0%20.7%21.1%24.4%19.0%19.4%20.0%22.6%
PAT (₹cr)862278145989133-52199
↳ change QoQ-96.9%+199.3%+466.0%-80.6%+49.4%-139.1%+482.7%
Net margin25.1%0.8%2.1%10.4%2.3%3.1%-1.3%4.4%
EPS (₹)5.51-0.130.212.870.230.631.080.78
D/E
YoY growth · Mar '26Revenue +2.3% YoYPAT -56.6% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 9 Sep '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Sep '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 Aug '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Aug '26
    LOWgovernance
    Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Aug '26
    LOWgovernance
    Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    MEDIUMgovernance
    Resignation

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    MEDIUMgovernance
    Change in Director(s)

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    HIGHgovernance
    Change in Auditors

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    MEDIUMgovernance
    Appointment

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds BIOCON

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma